Intravenous bisphosphonate therapy and atrial fibrillation/flutter risk in cancer patients: A nationwide cohort study

British Journal of Cancer

Volumn 105, Issue 7, 2011, Pages 881-883

  Erichsen, R ^a   Christiansen, C F ^a   Froslev T ^a   Jacobsen, J ^a   Sorensen H T ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

atrial fibrillation; diphosphonates; neoplasms; risk

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOMA; PRIORITY JOURNAL;

AGED; ATRIAL FIBRILLATION; ATRIAL FLUTTER; BONE DENSITY CONSERVATION AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; DENMARK; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80053260408     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.338     Document Type: Article

References (27)

1. Abrahamsen B, Eiken P, Brixen K (2009) Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med 265(5): 581-592
2. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH (1999) The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 46(3): 263-268 (Pubitemid 29299976)
3. Arslan C, Aksoy S, Dizdar O, Dede DS, Harputluoglu H, Altundag K (2011) Zoledronic acid and atrial fibrillation in cancer patients. Support Care Cancer 19(3): 425-430
4. Bhuriya R, Singh M, Molnar J, Arora R, Khosla S (2010) Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol 142(3): 213-217
5. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18): 1809-1822 (Pubitemid 46698462)
6. Bunch TJ, Anderson JL, May HT, Muhlestein JB, Horne BD, Crandall BG, Weiss JP, Lappe DL, Osborn JS, Day JD (2009) Relation of bisphos-phonate therapies and risk of developing atrial fibrillation. Am J Cardiol 103(6): 824-828
7. Christiansen CF, Christensen S, Mehnert F, Cummings SR, Chapurlat RD, Sorensen HT (2009) Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study. Arch Intern Med 169(18): 1677-1683
8. Coleman RE, Guise TA, Lipton A, Roodman GD, Berenson JR, Body JJ, Boyce BF, Calvi LM, Hadji P, McCloskey EV, Saad F, Smith MR, Suva LJ, Taichman RS, Vessella RL, Weilbaecher KN (2008) Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res 14(20): 6387-6395
9. Ehrenstein V, Antonsen S, Pedersen L (2010) Existing data sources for clinical epidemiology: Aarhus University prescription database. Clin Epidemiol 2: 273-279
10. FDA. Update of safety review follow-up to the October 1, 2007 early communication about the ongoing safety review of bisphosphonates. 12 Nov 2008 (online), 3 March 2010, 10 March 2011. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm136201.htm
11. Frost L, Vestergaard P (2004) Alcohol and risk of atrial fibrillation or flutter: a cohort study. Arch Intern Med 164(18): 1993-1998 (Pubitemid 39390555)
12. Grosso A, Douglas I, Hingorani A, MacAllister R, Smeeth L (2009) Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. PLoS One 4(3): e4720
13. Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM (2008) Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 168(8): 826-831 (Pubitemid 351649266)
14. Howard PA, Barnes BJ, Vacek JL, Chen W, Lai SM (2010) Impact of bisphosphonates on the risk of atrial fibrillation. Am J Cardiovasc Drugs 10(6): 359-367
15. Huang WF, Tsai YW, Wen YW, Hsiao FY, Kuo KN, Tsai CR (2010) Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene. Menopause 17(1): 57-63
16. Karam R, Camm J, McClung M (2007) Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med 357(7): 712-713 (Pubitemid 47267247)
17. Kim SY, Kim MJ, Cadarette SM, Solomon DH (2010) Bisphosphonates and risk of atrial fibrillation: a meta-analysis. Arthritis Res Ther 12(1): R30
18. Loke YK, Jeevanantham V, Singh S (2009) Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf 32(3): 219-228
19. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18): 1799-1809 (Pubitemid 350044800)
20. Mak A, Cheung MW, Ho RC, Cheak AA, Lau CS (2009) Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskelet Disord 10: 113
21. Pedersen CB, Gotzsche H, Moller JO, Mortensen PB (2006) The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 53(4): 441-449 (Pubitemid 44816920)
22. Sorensen HT, Christensen S, Mehnert F, Pedersen L, Chapurlat RD, Cummings SR, Baron JA (2008) Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 336(7648): 813-816 (Pubitemid 351548223)
23. Sorensen HT, Lash TL, Rothman KJ (2006) Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies. Hepatology 44(5): 1075-1082 (Pubitemid 44748358)
24. Storm HH, Michelsen EV, Clemmensen IH, Pihl J (1997) The Danish Cancer Registry-history, content, quality and use. Dan Med Bull 44(5): 535-539
25. Vestergaard P, Schwartz K, Pinholt EM, Rejnmark L, Mosekilde L (2010) Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study. Calcif Tissue Int 86(5): 335-342
26. Wilkinson GS, Baillargeon J, Kuo YF, Freeman JL, Goodwin JS (2010) Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer. J Clin Oncol 28(33): 4898-4905
27. Woolf AD, Akesson K (2003) Preventing fractures in elderly people. BMJ 327(7406): 89-95 (Pubitemid 36836461)